Real-World Safety of NOACs: What Do We Know Today?

Slides:



Advertisements
Similar presentations
Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.
Advertisements

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.
Gli anticoagulanti diretti nel mondo reale
TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Non-valvular Atrial Fibrillation.
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international,
Major Depressive Disorder: Latest Clinical Update
Anticoagulant Safety Remains a Problem Emergency Hospitalizations for Adverse Drug Events.
NOACs for Cancer-Associated Thrombosis:
Anticoagulants in Interventional Cardiology:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
POWER IN NUMBERS: REVISITING EFFICACY & SAFETY OF NOACS IN AF
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
New Perspectives in CAD and PAD: Weighing the Latest Evidence
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
The Essentials for Secondary Stroke Prevention
New Oral Anticoagulants and VTE Management
VTE Treatment Conventional Approach
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
NOACS: Emerging data in ACS/IHD
Access to NOAC Therapy:
Adherence in SPAF: Measures to Improve Care
What Anticoagulant Registries Are Revealing
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Oral Anticoagulation in AF
Real-World Evidence in VTE
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
A Case Challenge.
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Which NOAC and When for Stroke Prevention in AF?
Updates in Anticoagulation: Key Sessions at ESC 2017
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
Real-World Evidence: What Is It and Why Is It so Important In MS?
Program Goals Background: Anticoagulation in Patients With VTE.
The ABCs of AF.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
5 Good Minutes on Atrial Fibrillation-related Stroke
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Real-World Data in Cardiology: Focus on Atrial Fibrillation
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Real-World Safety of NOACs: What Do We Know Today?

Program Goals

NOACs: A Revolution in the Management of Thrombotic Disorders

Clinical Trials Vs Real World Evidence (RWE)

Spectrum of Real World Trials

Strengths and Weaknesses of Real World Trials

XANTUS: A Prospective Registry

XANTUS

Recently Published Claims Databases*

Recently Published Claims Database Analyses of Rivaroxaban vs VKA for NVAF and Comparison of Results to ROCKET AF

Recently Published Claims Database Analyses of Apixaban vs VKA for NVAF and Comparison of Results to ARISTOTLE

Recently Published Claims Database Analyses of Dabigatran Vs VKA for NVAF and Comparison of Results to RE-LY

Claims Database NOACs

XALIA A Prospective, Non-Interventional Study

XALIA: Propensity Score Adjustment

Treatment-Emergent Clinical Outcomes (Propensity-Score Adjusted Comparison)

EINSTEIN CHOICE Study Design

EINSTEIN CHOICE: Primary Outcome Recurrent VTE

EINSTEIN CHOICE: Bleeding Outcomes

Concluding Remarks

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.